Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2026Biomedicine & PharmacotherapyOpen Access

A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYuxuan LiuXLXiaojun Liu

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates metabolic effects of a trispecific peptibody in diet-induced obesity models, highlighting its multifaceted benefits.

Key Points

  • This research aims to assess the pharmacological activity of a trispecific peptibody targeting GLP-1R, GIPR, and FGF21 for metabolic diseases.
  • Generated trispecific peptibody using an antibody-based scaffold
  • Characterized using in vitro binding and receptor activation assays
  • Evaluated in vivo efficacy in a diet-induced obesity mouse model, measuring body weight, glucose tolerance, and serum analyses.
  • The trispecific construct reduced body weight in DIO mice, with a reduction of X grams (exact value not specified).
  • Improved glucose tolerance was noted, suggesting enhanced metabolic function.
  • Significant improvements in lipid profiles and liver parameters were observed, indicating broader metabolic benefits beyond appetite suppression.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6a44af635cd2549c8bc4463chttps://doi.org/10.1016/j.biopha.2026.119717
View Full Paper
Ask AI
Bookmark
Share